Neoadjuvant therapy is offered whenever initial evaluation reveals a high risk peritoneal mesothelioma (peritoneal cancer index > 17, Ki-67 > 9%, sarcomatoid histology, nodal positive status, incomplete resection CC score >1), and/or borderline resectability. This evidence concerns the gene MKI67 and peritoneal mesothelioma.